GFWA
REGN icon

Grey Fox Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Grey Fox Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-165
Closed -$92.8K – 492
2025
Q3 		$92.8K Buy
+165
New +$93.3K 0.02% 200
2024
Q3 		– Sell
-195
Closed -$205K – 141
2024
Q2 		$205K Buy
+195
New +$189K 0.07% 123
2023
Q2 		– Sell
-279
Closed -$229K – 417
2023
Q1 		$229K Hold
279
– – 0.14% 84
2022
Q4 		$201K Buy
+279
New +$206K 0.13% 92

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Grey Fox Wealth Advisors's REGN Position: Q4 2025 in Review

Grey Fox Wealth Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 165 shares — an estimated $92.8K sold.

Grey Fox Wealth Advisors first reported a position in REGN in Q4 2022 and held it in 4 quarters. The position peaked at $229K in Q1 2023. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Grey Fox Wealth Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Grey Fox Wealth Advisors sold 165 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $92.8K.
  • Grey Fox Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Grey Fox Wealth Advisors's Regeneron Pharmaceuticals position peaked at $229K in Q1 2023.
  • 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Grey Fox Wealth Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.